Morgan Stanley
ACHV icon

Morgan Stanley’s Achieve Life Sciences ACHV Stock Holding History

Morgan Stanley’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$207K Sell
70,378
-8,683
-11% -$38.6K ﹤0.01% 5853
2025
Q4 		$393K Buy
79,061
+45,414
+135% +$198K ﹤0.01% 5634
2025
Q3 		$106K Sell
33,647
-72,650
-68% -$199K ﹤0.01% 6123
2025
Q2 		$240K Buy
106,297
+43,159
+68% +$123K ﹤0.01% 5782
2025
Q1 		$169K Sell
63,138
-13,077
-17% -$40.7K ﹤0.01% 5808
2024
Q4 		$268K Sell
76,215
-14,446
-16% -$65.5K ﹤0.01% 5679
2024
Q3 		$430K Buy
90,661
+57,884
+177% +$264K ﹤0.01% 5471
2024
Q2 		$154K Buy
+32,777
New +$158K ﹤0.01% 5784
2023
Q4 		– Sell
-2,200
Closed -$9.46K – 7823
2023
Q3 		$9.46K Sell
2,200
-1,600
-42% -$8.06K ﹤0.01% 6749
2023
Q2 		$19.7K Hold
3,800
– – ﹤0.01% 6575
2023
Q1 		$25.8K Sell
3,800
-9,747
-72% -$46.3K ﹤0.01% 6536
2022
Q4 		$33.2K Buy
13,547
+11,026
+437% +$28.3K ﹤0.01% 6466
2022
Q3 		$8K Buy
2,521
+21
+0.8% +$100 ﹤0.01% 7137
2022
Q2 		$12K Sell
2,500
-3,949
-61% -$26.8K ﹤0.01% 7157
2022
Q1 		$49K Sell
6,449
-48,557
-88% -$362K ﹤0.01% 6711
2021
Q4 		$428K Sell
55,006
-55,863
-50% -$439K ﹤0.01% 5638
2021
Q3 		$942K Sell
110,869
-28,331
-20% -$222K ﹤0.01% 5086
2021
Q2 		$1.25M Buy
139,200
+51,654
+59% +$492K ﹤0.01% 4950
2021
Q1 		$1.01M Buy
87,546
+87,545
+8,754,500% +$1.04M ﹤0.01% 4722
2020
Q4 		$0 Sell
1
-15,918
-100% -$135K ﹤0.01% 7027
2020
Q3 		$133K Buy
15,919
+15,918
+1,591,800% +$146K ﹤0.01% 5294
2020
Q2 		$0 Hold
1
– – ﹤0.01% 6581
2020
Q1 		$0 Sell
1
-1,276
-100% -$12.3K ﹤0.01% 6553
2019
Q4 		$14K Buy
1,277
+427
+50% +$9.16K ﹤0.01% 6180
2019
Q3 		$28K Buy
850
+848
+42,400% +$33.3K ﹤0.01% 5910
2019
Q2 		$0 Sell
2
-6
-75% -$424 ﹤0.01% 6628
2019
Q1 		$0 Buy
8
+7
+700% +$283 ﹤0.01% 6575
2018
Q4 		$0 Sell
1
-50
-98% -$1.89K ﹤0.01% 6580
2018
Q3 		$3K Buy
51
+49
+2,450% +$3.1K ﹤0.01% 6502
2018
Q2 		$0 Hold
2
– – ﹤0.01% 6649
2018
Q1 		$0 Hold
2
– – ﹤0.01% 6595
2017
Q4 		$0 Hold
2
– – ﹤0.01% 6553
2017
Q3 		$0 Hold
2
– – ﹤0.01% 6520
2017
Q2 		$2K Hold
2
– – ﹤0.01% 6449
2017
Q1 		$2K Hold
2
– – ﹤0.01% 6449
2016
Q4 		$2K Hold
2
– – ﹤0.01% 6373
2016
Q3 		$3K Sell
2
-1
-33% -$1.59K ﹤0.01% 6312
2016
Q2 		$7K Sell
3
-7
-70% -$14.6K ﹤0.01% 6139
2016
Q1 		$15K Hold
10
– – ﹤0.01% 6016
2015
Q4 		$27K Sell
10
-9
-47% -$38K ﹤0.01% 5936
2015
Q3 		$92K Buy
19
+1
+6% +$6.03K ﹤0.01% 5457
2015
Q2 		$91K Sell
18
-2
-10% -$9.92K ﹤0.01% 5633
2015
Q1 		$95K Sell
20
-28
-58% -$138K ﹤0.01% 5551
2014
Q4 		$240K Buy
48
+3
+7% +$14.7K ﹤0.01% 5129
2014
Q3 		$262K Sell
45
-39
-46% -$271K ﹤0.01% 4995
2014
Q2 		$690K Buy
84
+51
+155% +$626K ﹤0.01% 4344
2014
Q1 		$855K Buy
33
+17
+106% +$418K ﹤0.01% 4125
2013
Q4 		$294K Buy
16
+6
+60% +$105K ﹤0.01% 4818
2013
Q3 		$202K Buy
10
+1
+11% +$20.7K ﹤0.01% 4882
2013
Q2 		$192K Buy
+9
New +$201K ﹤0.01% 4862

Other funds holding ACHV

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley's ACHV Position: Q1 2026 in Review

Morgan Stanley reduced its Achieve Life Sciences (ACHV) stake by 11% in Q1 2026, selling an estimated $38.6K and leaving 70,378 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #5853.

Morgan Stanley first reported a position in ACHV in Q2 2013 and has held it in 50 quarters since. The position peaked at $1.25M in Q2 2021. 81 funds tracked by Wall St. Rank hold ACHV as of Q1 2026.

  • Morgan Stanley held 70,378 shares of Achieve Life Sciences worth $207K as of Q1 2026.
  • Morgan Stanley sold 8,683 Achieve Life Sciences shares in Q1 2026, an estimated $38.6K.
  • Achieve Life Sciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5853 holding.
  • Morgan Stanley first reported a position in Achieve Life Sciences in Q2 2013 and has held it in 50 quarters since.
  • Morgan Stanley's Achieve Life Sciences position peaked at $1.25M in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.